 Home > Medical News > Latest Medical News > Interleukin-6 receptor antagonist included in the new crown treatment plan

Interleukin-6 receptor antagonist included in the new crown treatment plan

 Last Update: 2021-07-29
 Source: Internet
 Author: User

Tags

purest water world

world account basf

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

WHO includes interleukin-6 receptor antagonist in new crown treatment plan

WHO includes interleukin-6 receptor antagonists in the new crown treatment plan WHO includes interleukin-6 receptor antagonists in the new crown treatment plan

Xinhua News Agency, Geneva, July 6.
The World Health Organization updated its guidelines on the care of patients with COVID-19 on the 6th, including interleukin-6 receptor antagonists in the list of available drugs
.

This is a class of drugs that have a life-saving effect on critically ill patients with new coronary disease, especially when used in combination with corticosteroids

This is the effective drug for the treatment of the new crown that has been reconfirmed since the WHO recommended the use of corticosteroids in September 2020
.

The WHO previously initiated a study of these drugs, which included data from more than 10,000 patients in 27 clinical trials
.

Critically ill patients with new coronary disease usually have an overreaction of the immune system, and tocilizumab and other interleukin-6 receptor antagonists can suppress this overreaction

Studies have shown that compared with standard treatments, the use of interleukin-6 receptor antagonists in critically ill patients with new coronary disease can reduce the mortality rate by 13%, and the number of deaths per 1,000 critically ill patients can be reduced by 28, and mechanical ventilation for critically ill patients The odds of deficiencies have been reduced by 28%, and the number of patients requiring mechanical ventilation can be reduced by 23 per thousand
.

WHO Director-General Tedros Adhanom Ghebreyesus said in a statement issued on the same day that these drugs bring hope to critically ill patients and their families
.

But for most people in the world, interleukin-6 receptor antagonists are still difficult to obtain and unaffordable

The WHO calls on pharmaceutical companies to lower prices and supply drugs to low- and middle-income countries, especially those with a surge in new crown cases

Focus on the new crown pneumonia epidemic

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.